Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

USPSTF Lowers the Recommended Age for CRC Screenings, Mandating Insurance Coverage

May 18, 2021
By Audrey Sternberg
News
Article

Recommendations published in JAMA are set to change colorectal cancer screening guidance for all individuals in the United States.

An update to the U.S. Preventive Services Task Force (USPSTF) recommendations now indicate that screening for colorectal cancer (CRC) should begin at age 45 years for all patients regardless of baseline characteristics, according to guidelines published in JAMA.1

This is a follow-up to draft guidance that was issued in October 2020 amending the recommended age of screening from 50 to 45 years of age and will mandate insurance coverage of screening for CRC.

These efforts by the task force are in large part a reaction to the alarming rise in the incidence of young-onset CRC, which occurs in patients younger than 50 years of age. By 2040, this is projected to be the leading cause of cancer deaths in patients ages 20 to 49 years.

This increasing incidence has been documented since the 1990s, but the proportion of patients with young-onset disease has accelerated rapidly over the last 10 years, with 11% of colon cancers and 15% of rectal cancers occurring in patients under the age of 50 years in 2020 compared with just 5% and 9%, respectively, in 2010.

“Clearly the USPSTF recommendation to start screening at age 45 will not be enough to catch those young people who are being diagnosed, but we must take bold steps to translate the lowered age of beginning screening into meaningful decreases in CRC incidence and mortality,” Kimmie Ng, MD, MPH, director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute and author of an accompanying editorial, said in a press release.2,3 “Lowering the recommended age to initiate screening will make colorectal cancer screening available to millions more people in the United States, and hopefully many more lives will be saved by catching colorectal cancer earlier, as well as by preventing colorectal cancer.”

Age 45 was selected by the task force based on evidence that averting more early deaths was possible versus starting at age 50 with a relatively small increase in the number of complications from colonoscopy. Of note, the new recommendation does not change guidance regarding screening in older individuals, with patients aged 76 to 85 years recommended for selective screening only.

In the editorial, Ng and colleagues point out that screenings at age 45 will not be enough to catch all cases of early-onset CRC, as the rate of colon cancer shows the steepest increase in patients aged 20 to 29 years at 2% versus 1.3% in those 40 to 49 years. Corresponding rates in rectal cancer were 3.2% and 2.3%, respectively.

“We are now seeing patients even younger than 45—in their 20s and 30s—who are being diagnosed with this cancer and often at very late stages,” Ng said. “Clearly the USPSTF recommendation to start screening at age 45 will not be enough to catch those young people who are being diagnosed.”

With the prior recommendations, less than 70% of patients who were eligible for screening received the preventative benefit, with patients who are uninsured or underinsured, those with lower incomes, and racial and ethnic minorities being disproportionately underserved. CRC is a disease that disproportionately affects African Americans, as they have a 20% greater likelihood of developing the tumor and a 40% greater risk of dying from it. As such, Ng and colleagues said addressing these public health barriers will be necessary to raise screening adherence.

References

1. US Preventive Services Task Force. Screening for Colorectal CancerUS Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238

2. Ng K, May FP, Schrag D. US Preventive Services Task Force Recommendations for Colorectal Cancer ScreeningForty-Five Is the New Fifty. JAMA. 2021;325(19):1943-1945. doi:10.1001/jama.2021.4133

'45 is the new 50' as age for colorectal cancer screening is lowered. News release. Dana-Farber Cancer Institute. May 18, 2021. Accessed May 18, 2021. https://bit.ly/3bBK1DT

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content
Advertisement

For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC

Roman Fabbricatore
May 19th 2025
Article

For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD
May 15th 2025
Article

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Roman Fabbricatore
May 8th 2025
Article

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.


Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Tim Cortese
May 5th 2025
Article

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.

Related Content
Advertisement

For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC

Roman Fabbricatore
May 19th 2025
Article

For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease

Meghana Kesireddy, MBBS;Rosalyn Marar, MD;Kaeli Samson, MA, MPH;Nicole A. Shonka, MD
May 15th 2025
Article

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.


Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.


Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Roman Fabbricatore
May 8th 2025
Article

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.


Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Workplace Burnout Among Oncologists Has Risen: What Can Be Done?

Tim Cortese
May 5th 2025
Article

Results from a recent survey showed that 20% of oncologists planned to reduce their hours in the next 12 months, as workplace burnout among them has increased.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.